Alf Grandien

Alf Grandien

Auto-generated profile, based on publicly available information

Alf Grandien

Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KHKari Högstrand
Kari Högstrand
EHEduar Hejll
Eduar Hejll
BSBirgitta Sander
Birgitta Sander
BRBjörn Rozell
Björn Rozell
LLLars-Gunnar Larsson
Lars-Gunnar Larsson
AGAlf Grandien
Alf Grandien
Myc plays an important role in tumor development, including acute myeloid leukemia (AML). However, MYC is also a powerful inducer of apoptosis, which is one of the major failsafe programs to prevent cancer development. To clarify the relative importance of the extrinsic (death receptor-mediated) versus the intrinsic (mitochondrial) pathway of apoptosis in MYC-driven AML, we coexpressed MYC together with anti-apoptotic proteins of relevance for AML; BCL-XL/BCL-2 (inhibiting the intrinsic pathway) or FLIPL (inhibiting the extrinsic pathway), in hematopoietic stems cells (HSCs). Transplantation of HSCs expressing MYC into syngeneic recipient mice resulted in development of AML and T-cell lymphomas within 7–9 weeks as expected. Importantly, coexpression of MYC together with BCL-XL/BCL-2 resulted in strongly accelerated kinetics and favored tumor development towards aggressive AML. In contrast, coexpression of MYC and FLIPL did neither accelerate tumorigenesis nor change the ratio of AML versus T-cell lymphoma. However, a change in distribution of immature CD4+CD8+ versus mature CD4+ T-cell lymphoma was observed in MYC/FLIPL mice, possibly as a result of increased survival of the CD4+ population, but this did not significantly affect the outcome of the disease. In conclusion, our findings provide direct evidence that BCL-XL and BCL-2 but not FLIPL acts in synergy with MYC to drive AML development.

12 October 2018 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
KHKari Högstrand
Kari Högstrand
AGAlf Grandien
Alf Grandien

1 March 2001 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
DCDaniel Corcos
Daniel Corcos
AGAlf Grandien
Alf Grandien
AVAime Vazquez
Aime Vazquez
ODOlga Dunda
Olga Dunda
PLPatrick Lorès
Patrick Lorès
DBDanielle Bucchini
Danielle Bucchini
Neoplastic B cells from H chain disease patients express a truncated B cell receptor (BCR), comprising a membrane Ig that lacks part of its extracellular domain. It has been speculated that deletion of the Ag binding domain would confer a constitutive activity on the BCR, as it has been shown for oncogenic growth factor receptors. A V region-less BCR has constitutive activity, because in transgenic mice it causes inhibition of endogenous H chain gene rearrangements and relieves the requirement for surrogate L chain in pre-B cell development. However, it has been speculated that normal Ag receptors also display constitutive activity. Here we show that transgenic B cells expressing a membrane H chain disease protein on their surface are phenotypically and functionally similar to B cells developing in the presence of their cognate Ag and that cells with normal levels of mutant BCR are eliminated in spleen via a bcl-2 sensitive pathway while progressing toward the mature stage. In contrast, cells with lower levels of mutant receptors develop as mature B cells. These findings support the view that the truncated BCR has a constitutive activity that mimics ligand binding, in analogy to what has been shown for oncogenic growth factor receptors.

20 April 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
KHKari Högstrand
Kari Högstrand
SDStephanie Darmanin
Stephanie Darmanin
TFTachaZi Plym Forshell
TachaZi Plym Forshell
AGAlf Grandien
Alf Grandien
Transformation of mouse T cells requires MYC and AKT activity in conjunction with inhibition of intrinsic apoptosis Transformation of mouse T cells requires MYC and AKT activity in conjunction with inhibition of intrinsic apoptosis

31 July 2007 in Scandinavian Journal of Immunology
Verified
Journal Article
Open access
PDF file
MDM. Djerbi
M. Djerbi
MMM. M. Malinowski
M. M. Malinowski
HYH. Yagita
H. Yagita
BZBoris Zhivotovsky
Boris Zhivotovsky
AGA. Grandien
A. Grandien
Apart from the conventional Fas signalling pathway, alternative pathways including the mitochondrial caspase‐dependent and RIP‐mediated cell death routes have been proposed to operate during Fas‐mediated cell death. To evaluate the contribution of different Fas signalling pathways, mice overexpressing FLIPL, Bcl‐xL, a kinase‐deficient form of RIP (RIPΔkin) or combinations thereof were generated by retroviral gene transfer of haematopoietic stem cells. Such mice did not show overt abnormalities in haematopoietic development, defects in thymic deletion, accumulation of double‐negative T cells or signs of autoimmunity. Fas‐mediated death of mitogen‐activated T cells was caspase dependent and could be blocked by FLIPL overexpression only with the minor involvement of Bcl‐xL or RIPΔkin inhibitable pathways. Fas‐mediated death of resting CD4+ and CD8+ T cells was mainly caspase dependent but could only partly be blocked by FLIPL overexpression. Both Bcl‐xL or RIPΔkin expression resulted in partial protection of CD8+ T cells against Fas‐mediated cell death. These results indicate that yet uncharacterized signalling pathways from the Fas receptor are critically involved in lymphoproliferative and autoimmune disease observed in lpr mice and autoimmune lymphoproliferative syndrome patients.

21 January 2019 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
KHKari Högstrand
Kari Högstrand
JLJessica M. Lindvall
Jessica M. Lindvall
ASAnne Sundblad
Anne Sundblad
AGAlf Grandien
Alf Grandien
An experimental system where defined alterations in gene function or gene expression levels in primary B cells would result in the development of transformed plasma cells in vitro would be useful in order to facilitate studies of the underlying molecular mechanisms of plasma cell malignancies. Here, such a system is described in which primary murine B cells rapidly become transformed into surface CD138+, IgM−/low, CD19− IgM‐secreting plasma cells as a result of expression of the transcription factors IRF4 and MYC together with simultaneous expression of BMI1, mutated p53 or silencing of p19Arf, and suppression of intrinsic apoptosis through expression of BCLXL. Analysis of gene expression patterns revealed that this combination of transforming genes resulted in expression of a number of genes previously associated with terminally differentiated B cells (plasma cells) and myeloma cells, whereas many genes associated with mature B cells and B‐cell lymphomas were not expressed. Upon transplantation, the transformed cells preferentially localized to the bone marrow, presenting features of a plasma cell malignancy of the IgM isotype. The present findings may also be applicable in the development of novel methods for production of monoclonal antibodies.